China Greatwall Securities Co.Ltd(002939)
about
Sonoscape Medical Corp(300633) issue shares to specific objects in 2020
of
Listing recommendation
Sponsor (lead underwriter)
(floors 10-19, South Tower, energy building, No. 2026, Jintian Road, Futian street, Futian District, Shenzhen) December, 2001
catalogue
catalogue 1 declare that 2 I. overview of the issuer 1. II. This issuance 18 III. introduction to the sponsor, sponsor representative and project team members 22 IV. description of the interests and main business transactions between the recommendation institution and its related parties and the issuer and its related parties 23 v. commitments of the sponsor Vi. explanation of the recommendation institution on whether the issuer has fulfilled the decision-making procedures stipulated in the company law, the securities law and the CSRC and Shenzhen stock exchange with respect to the issuance and listing of Securities 25 VII. Explanation that the application for securities issuance and listing meets the listing conditions VIII. Specific arrangements of the recommendation institution for the continuous supervision of the issuer’s securities after listing IX. other matters that the recommendation institution deems necessary to explain X. recommendation conclusion of the recommendation institution on the issuer’s listing of shares twenty-seven
statement
China Greatwall Securities Co.Ltd(002939) accepted the entrustment of Sonoscape Medical Corp(300633) to act as the sponsor for the issuance of shares to specific objects in Sonoscape Medical Corp(300633) 2020 and issue the listing recommendation letter for this issuance.
In accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”) and the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”) The measures for the administration of securities issuance and registration of companies listed on the gem (for Trial Implementation) (hereinafter referred to as the “measures for the administration of registration”) and other relevant laws and regulations, as well as the relevant provisions of the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) and Shenzhen Stock Exchange (hereinafter referred to as the “Shenzhen Stock Exchange”), are honest, trustworthy, diligent and responsible, The listing recommendation letter shall be issued in strict accordance with the business rules, industry practice norms and ethical standards formulated according to law, and the authenticity, accuracy and integrity of the documents issued shall be guaranteed.
1、 Overview of the issuer (I) basic information of the issuer
Chinese name of the company: Sonoscape Medical Corp(300633)
English name of the company: sonoscape medical Corp
Listing place: Shenzhen Stock Exchange
Securities abbreviation: Sonoscape Medical Corp(300633)
Securities code: 300633 SZ
Registered address: 201202, building 12, Shenzhen Software Park (phase 2), No. 1, kekekezhong 2 Road, high tech Zone, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong
Office address: 201202, building 12, Shenzhen Software Park (phase 2), No. 1, kekekezhong 2 Road, high tech Zone, Maling community, Yuehai street, Nanshan District, Shenzhen, Guangdong
Date of establishment of the joint stock company: December 31, 2014
Legal representative: Chen Zhiqiang
Registered capital: 401920000 yuan
Unified social credit Code: 91440300743219767a
General business items are: software development of medical devices (excluding items restricted by the state); Biotechnology development, technology transfer, technical services and technical consultation; Technical and business scope of self-produced products: technical maintenance services; After sales service of self-produced products; Operate import and export business (except for projects prohibited by laws, administrative regulations and decisions of the State Council, and restricted projects can be operated only after obtaining permission). The licensed business items are: production and operation of medical devices and their supporting reagents and product software development; Production and operation of display products and electronic products.
Company website: www.sonoscape.com com.
Contact: 86-755-26722890
（2） Business information of the issuer
The company is mainly engaged in the independent R & D, production and sales of medical diagnosis and treatment equipment. The main products include medical ultrasonic diagnostic equipment (mainly color Doppler ultrasonic diagnostic equipment and B-mode ultrasonic diagnostic equipment), medical electronic endoscope equipment and consumables, blood analyzer, etc. In terms of medium and long-term product line layout, in addition to ultrasound and soft mirror product lines, the company’s intravascular ultrasound (IVUS), ultrasound endoscopy, soft mirror treatment instruments, hard mirror and other product lines are also in the R & D pipeline. The overall product technology positioning is leading. Some products fill the gap in relevant fields in China’s medical device industry, and the company’s multi product line strategy is gradually taking shape.
According to the classification standard of national economic industry classification (GB / T 4754-2011) issued by the National Bureau of statistics, the company’s industry belongs to the sub industry “medical diagnosis, monitoring and treatment equipment manufacturing” under “medical instrument and equipment manufacturing” in the 35th category of “professional equipment manufacturing”. According to the industry classification guidelines for listed companies (revised in 2012) of China Securities Regulatory Commission, the company belongs to the special equipment manufacturing industry (classification code: C35). （3） Core technology
After long-term technological and product innovation, the company has accumulated a large number of core technologies in the R & D process. By the end of September 2021, the company’s main core technologies are as follows:
1. Medical image synthesis technology
Sequence technology name, technical characteristics and application stage
Through multiple compound sound fields, the equivalent beam has smaller sidelobe and consistency
1 the ultrasonic beam control has a longer focal area. The side lobe and consistency of the sound field determine the contrast resolution of the image, large-scale production technology and spatial resolution. At the same time, it also has better consistency in the medium, near and far fields, which is generally consistent with the production
Beam reconstruction techniques are used together.
Through multi beam and beam phase correction coherent composite imaging technology, the image quality can be improved
Horizontal resolution, PSF (point spread function) display
2 spatiotemporal beam heavy lifting. For multiple images at different times and positions, for two-dimensional images, the final large-scale production algorithm creates images with high resolution and high contrast resolution, which can ensure high full field resolution
For Doppler imaging, multi beam can be effectively used to achieve higher blood flow rate
Flow imaging frame rate and blood flow signal-to-noise ratio.
Adopt the newly developed transmission and beam synthesis technology, combined with new hardware processing
3. The fast imaging technology platform provides an imaging capability of more than 5000 frames / s. The fast imaging technology can be tested on a small scale to effectively improve the time resolution of each imaging mode of the whole machine, and sample in time
Better consideration of resolution, spatial resolution and image penetration.
Ultrasonic quantitative measurement of fatty liver attenuation imaging adopts Sonoscape Medical Corp(300633) patented technology to intelligently analyze the small-scale test 4 measurement data of liver echo number, and finally calculate the attenuation coefficient of liver. Attenuation coefficient for sample
Clinical evaluation of fatty liver has good clinical value.
Sonoscape Medical Corp(300633) has a number of authorized invention patents for contrast imaging technology, and contrast imaging is beneficial
Using ultrasound combined with the nonlinear response characteristics of contrast agent microbubbles, through a special contrast medium
The signal imaging of contrast microbubbles is extracted by contrast-enhanced ultrasound imaging sequence and received echo extraction technology, and the blood perfusion of lesions is evaluated by the development of developer microbubbles in large-scale imaging technology, which is used for the production of lesions
Auxiliary diagnosis. Contrast imaging has important diagnostic significance. At present, it is widely used in shallow
Table applied parts of small organs, abdomen, cardiovascular, uterine accessories and fallopian tubes.
Contrast microvascular imaging technology mainly uses image superposition processing and maximum intensity projection
The changes of contrast medium in the process of flowing through blood vessels and microvessels were recorded
In the footprints, we can see the image of micro blood vessels through which the contrast medium flows.
Contrast time imaging is to record the maximum intensity projection of microvascular imaging at the same time
When the projection point under the contrast microvascular is projected, a color image is obtained, which takes the projection time and time of each pixel point as the content and encodes different times with different colors
Imaging technology perfusion time image (or time of arrival imaging). From the image can be different
The color clearly shows the time when the contrast medium reaches different positions. Contrast Microblood
Tube imaging can see the image of micro blood vessels with contrast medium flowing through, which is more convenient for diagnosis
Break; Contrast time imaging can be clearly seen from the image according to different colors
The time when the agent reaches different positions.
Sequence technology name, technical characteristics and application stage
Rainbow perfusion imaging is a Sonoscape Medical Corp(300633) unique technology, which is the basis of hysterosalpingography
Based on the extracted features, the time difference three-dimensional volume is obtained. Timing
After growth and color filling (according to the time pseudo color mapping relationship)
7 rainbow perfusion into three-dimensional volume (color filling) for three-dimensional rendering, so as to obtain spatiotemporal perfusion three-dimensional image. Clinical significance of large-scale imaging technology: develop according to different arrival times to more accurately evaluate bilateral fallopian samples
The patency of the tube; Assess whether there is venous reflux, which is sometimes associated with fallopian tube development
When there is a difference, it is conducive to the identification of countercurrent image; It is better to identify the direction of pelvic diffusion
To determine which side of the fallopian tube the pelvic diffuse contrast medium comes from.
High definition three-dimensional imaging technology can reconstruct and obtain three-dimensional ultrasonic images and high-definition four-dimensional imaging
Technology can dynamically obtain three-dimensional ultrasound images in different time periods, mainly through control
High definition three-dimensional / system motor swing to obtain ultrasonic images at different positions in space, using reconstruction technology and
8 four dimensional imaging technology rendering imaging technology to obtain the corresponding three-dimensional / four-dimensional imaging. 3D / 4D imaging technology large-scale biotechnology also includes color3d, stic (time-space correlation imaging, production)
Spatial temporal imaging correlation), stic color, volume thickness
Imaging function, tomography, free anatomical imaging, three-dimensional follicular automatic measurement, etc
Image function provides a more powerful guarantee for the diagnosis of Obstetrics and gynecology.
Multi-scale super-resolution analysis is used to suppress noise and speckle
µ – scan is made more naturally, and the image contrast and spatial resolution are effectively improved. When compared with large-scale image generation 9 technology, the complexity of the algorithm depends less on hardware, and the effect and real-time performance of the algorithm can be produced
To guarantee. µ – scan advanced image processing enables intelligent image processing without loss of information
It can suppress speckle noise and enhance tissue sensitivity
